

List of 2022 New Studies by Working Committee



Working Committee	Study #	Study Title	PI
Acute Leukemia	LK22-01	Intensive induction chemotherapy vs. hypomethylating agent therapy for older AML patients undergoing allogeneic hematopoietic cell transplantation	Naveed Ali
Cellular Immunotherapy for Cancer	CT22-01	CD19-CAR-T therapy failure: Impact of subsequent therapy in patients with B-cell malignancies	Lohith Gowda/ Guru Subramanian Guru Murthy
Cellular Immunotherapy for Cancer	CT22-02	Machine learning for predicting toxicity and early clinical outcomes in DLBCL and B-ALL patients treated with commercial CAR T products in the real-world setting: an analysis of the CIBMTR registry	Ana Alarcon Tomas /Lauren Appell/ Evandro Bezerra/ Abu-Sayeeef Mirza/ Miguel-Angel Perales/ Akshay Sharma/ Yi Lin/ Lohith Gowda/ Guru Subramanian Guru Murthy
Chronic Leukemia	CK22-01	Impact of somatic mutations on outcomes after allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T)	Shukaib Arslan/ Ryotaro Nakamura
Chronic Leukemia	CK22-02	Toxicity and survival of AML/MDS patients receiving allogeneic stem cell transplantation using reduced-intensity conditioning: A propensity score analysis	Piyanuch Kongtim/ Andrew Portuguese/ Stefan Ciurea/ Bart Scott
Graft Sources and Manipulation	GS22-01	HLA matched sibling versus well-matched unrelated donor: Update including HLA-DPB1 match status in recipients of allogeneic hematopoietic cell transplantation	Karthik Nath/ Brian Shaffer/ Hannah Choe
Graft-vs-Host Disease	GV22-01	Acute and chronic graft versus host disease in infants and toddlers following hematopoietic cell transplantation	Miki Nishitani/ Christine Duncan/ Rudi- Ann Graham/ Muna Qayed
Graft-vs-Host Disease	GV22-02	Chronic GVHD Risk Index: A clinical risk assessment score for development of moderate-severe chronic graft-versus-host disease after hematopoietic cell transplantation	Annie Im/ Steven Pavletic
Graft-vs-Host Disease	GV22-03	Does race/ethnicity or socio-economic status impact the outcomes of patients with acute GVHD?	Nahid Rashid/ Nosha Farhadfar
Immunobiology	IB22-01	Impact of HLA-DPB1 matching on survival following unrelated donor transplantation with post transplant cyclophosphamide for adults with hematologic malignancies	Amanda Blouin/ Ephraim Fuchs/ Uroosa Ibrahim
Immunobiology	IB22-02	Effect of SIRP α mismatch on the outcome of allogeneic hematopoietic stem cell transplantation from an HLA matched related donor	Jun Zou/ Samer Srour
Infection and Immune Reconstitution	IN22-01	Viral Hepatitis after allogeneic hematopoietic cell transplant using post-transplant cyclophosphamide for graft versus host disease prophylaxis	Kitsada Wudhikarn/ Miguel-Angel Perales

Late Effects and Quality of Life	EL22-01	Racial/ethnic disparities and role of poverty in long-term health outcomes among survivors of allogeneic hematopoietic cell transplant performed in childhood	Neel Bhatt/ Akshay Sharma/ Christine Duncan/ Lauren Jimenez-Kurlander
Lymphoma	LY22-01	Outcomes of CD19 CAR-T in patients who achieve complete remission prior to lymphodepletion in patients with aggressive non-Hodgkin's lymphoma	Mehdi Hamadani/ Mazyar Shadman/ Antonio Jiminez/ Trent Wang
Lymphoma	LY22-02	Efficacy and safety of CD19 directed CAR T-cell therapy for non-Hodgkin B-cell lymphomas with primary and secondary central nervous system involvement	Sairah Ahmed/ Santiago Mercadal/ Hamza Hashmi/ Catherine Joy Lee/ Narendranath Epperla
Non-Malignant Diseases	NM22-01	Outcomes after second or greater allogeneic stem cell transplants in patients with severe aplastic anemia: A contemporary analysis	Hemalatha Rangarajan/ Prakash Satwani
Pediatric Cancer	PC22-01	Impact of graft versus host disease following allogeneic hematopoietic cell transplantation on leukemia free survival in hematologic malignancies within the pediatric disease risk index risk stratification	Andrea Bauchat/ Muna Qayed
Pediatric Cancer	PC22-02	Evaluating predictors of access and outcomes with hematopoietic cell transplantation in pediatric and adolescent patients with relapsed/refractory classical Hodgkin lymphoma after treatment on an initial cooperative group clinical trial	Sharon Castellino/ Justin Kahn
Plasma Cell Disorders	MM22-01	Outcomes of autologous hematopoietic cell transplantation for light chain deposition disease	Hamza Hashmi/Binod Dhakal
Regimen-Related Toxicity and Supportive Care	EL22-02	Post-transplant cyclophosphamide related cardiomyopathy; incidence, risk factors and outcome: A retrospective review from CIBMTR database	Kittika Poonsombudlert/ Christopher Strouse/ Hemalatha Rangarajan/ Prakash Satwani/ Dipenkumar Modi